Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beatrice Detti

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Journal of Geriatric Oncology|December 10, 2022
Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapyGiulio Francolini, Giulio Frosini, Vanessa Di Cataldo, et al.
Frontiers in Oncology|April 7, 2023
Choline PET/CT in recurrent prostate cancerBeatrice Detti, Maria Grazia Carnevale, Sara Lucidi, et al.
La Radiologia Medica|December 1, 2021
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative settingGiulio Francolini, Giulia Stocchi, Beatrice Detti, et al.
La Radiologia Medica|June 28, 2022
Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)Giulio Francolini, Beatrice Detti, Vanessa Di Cataldo, et al.
La Radiologia Medica|January 5, 2019
High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experienceBeatrice Detti, Muhammed Baki, Carlotta Becherini, et al.
La Radiologia Medica|September 8, 2017
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO)Silvia Scoccianti, Marco Krengli, Livia Marrazzo, et al.
Frontiers in Oncology|September 24, 2024
Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?Andrea Lancia, Gianluca Ingrosso, Beatrice Detti, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 22, 2023
Modulation of tumor-associated macrophage activity with radiation therapy: a systematic reviewCarlotta Becherini, Andrea Lancia, Beatrice Detti, et al.
Future Oncology (London, England)|February 4, 2016
Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelinIcro Meattini, Calogero Saieva, Fiammetta Meacci, et al.
British Journal of Cancer|April 28, 2017
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric studyLuca Triggiani, Filippo Alongi, Michela Buglione, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Journal of Geriatric Oncology|December 10, 2022
Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapyGiulio Francolini, Giulio Frosini, Vanessa Di Cataldo, et al.
Frontiers in Oncology|April 7, 2023
Choline PET/CT in recurrent prostate cancerBeatrice Detti, Maria Grazia Carnevale, Sara Lucidi, et al.
La Radiologia Medica|December 1, 2021
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative settingGiulio Francolini, Giulia Stocchi, Beatrice Detti, et al.
La Radiologia Medica|June 28, 2022
Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)Giulio Francolini, Beatrice Detti, Vanessa Di Cataldo, et al.
La Radiologia Medica|January 5, 2019
High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experienceBeatrice Detti, Muhammed Baki, Carlotta Becherini, et al.
La Radiologia Medica|September 8, 2017
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO)Silvia Scoccianti, Marco Krengli, Livia Marrazzo, et al.
Frontiers in Oncology|September 24, 2024
Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?Andrea Lancia, Gianluca Ingrosso, Beatrice Detti, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 22, 2023
Modulation of tumor-associated macrophage activity with radiation therapy: a systematic reviewCarlotta Becherini, Andrea Lancia, Beatrice Detti, et al.
Future Oncology (London, England)|February 4, 2016
Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelinIcro Meattini, Calogero Saieva, Fiammetta Meacci, et al.
British Journal of Cancer|April 28, 2017
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric studyLuca Triggiani, Filippo Alongi, Michela Buglione, et al.
Pageof 12